Human small breast epithelial mucin: The promise of a new breast tumor biomarker

DNA and Cell Biology

Volumn 23, Issue 12, 2004, Pages 842-849

  Hube F ^a   Mutawe, M ^a   Leygue, E ^a   Myal, Y ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMAGLOBIN; MUCIN; MUCIN 1; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; EARLY DIAGNOSIS; GENE EXPRESSION; GENE STRUCTURE; GENE THERAPY; HUMAN; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RNA STRUCTURE; SERIAL ANALYSIS OF GENE EXPRESSION;

GENE THERAPY; HUMANS; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, ANIMAL; MUCINS; NEOPLASM METASTASIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 10344263396     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/1044549042729612     Document Type: Article

References (58)

1. AZIZ, S.A., PERVEZ, S., KHAN, S., KAYANI, N., and RAHBAR, M.H. (2002). Epidermal growth factor receptor (EGFR) as a prognostic marker: An immunohistochemical study on 315 consecutive breast carcinoma patients. J. Pak. Med. Assoc. 52, 104-10.
2. BARUCH, A., HARTMANN, M., ZRIHAN-LICHT, S., GREENSTEIN, S., BURSTEIN, M., KEYDAR, I., WEISS, M., SMORODINSKY, N., and WRESCHNER, D.H. (1997). Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int. J. Cancer. 29, 741-749.
3. CHANG, J.Y., XIA, W., SHAO, R., SORGI, F., HORTOBAGYI, G.N., HUANG, L., and HUNG, M.C. (1997). The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 14, 561-568.
4. CHENG, P.W. (1996). Receptor ligand-facilitated gene transfer: Enhancement of liposome-mediated gene transfer and expression by transferrin. Hum. Gene Ther. 7, 275-282.
5. CHEUNG, K.L., GRAVES, C.R., and ROBERTSON, J.F. (2000). Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat. Rev. 26, 91-102.
6. CIBOROWSKI, P., and FINN, O.J. (2002). Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: Potential role in metastasis. Clin. Exp. Metastasis 19, 339-345.
7. CLARK, H.F., GURNEY, A.L., ABAYA, E., BAKER, K., BALDWIN, D., BRUSH, J., CHEN, J., CHOW, B., CHUI, C., CROWLEY, C., et al. (2003). The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: A bioinformatics assessment. Genome Res. 13, 2265-2270.
8. CLARK, J.W., SNELL, L., SHIU, R.P., ORR, F.W., MAITRE, N., VARY, C.P., COLE, D.J., and WATSON, P.H. (1999). The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. Br. J. Cancer 81, 1002-1008.
9. COLPITTS, T.L., BILLING, P., GRANADOS, E., HAYDEN, M., HODGES, S., ROBERTS, L., RUSSELL, J., FRIEDMAN, P., and STROUPE, S. (2002). Identification and immunohistochemical characterization of a mucin-like glycoprotein expressed in early stage breast carcinoma. Tumour Biol. 23, 263-278.
10. DACHS, G.U., DOUGHERTY, G.J., STRATFORD, I.J., and CHAPLIN, D.J. (1997). Targeting gene therapy to cancer: A review. Oncol. Res. 9, 313-325.
11. ERMOLAEVA, O.D., and SVERDLOV, E.D. (1996). Subtractive hybridization, a technique for extraction of DNA sequences distinguishing two closely related genomes: critical analysis. Genet. Anal. 13, 49-58.
12. FOX, S.B., LEEK, R.D., SMITH, K., HOLLYER, J., GREENALL, M., and HARRIS, A.L. (1994). Tumor angiogenesis in node-negative breast carcinomas - Relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res. Treat. 29, 109-116.
13. FRANKEL, A.E. (1993). Immunotoxin therapy of cancer. Oncology 7, 69-86.
14. GODBEY, W.T., and ATALA, A. (2003). Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery. Gene Ther. 10, 1519-1527.
15. GUAN, X.F., HAMEDANI, M.K., ADEYINKA, A., WALKER, C., KEMP, A., MURPHY, L.C., WATSON, P.H., and LEYGUE, E. (2003). Relationship between mammaglobin expression and estrogen receptor status in breast tumors. Endocrine 21, 245-250.
16. HAAGENSEN, D.E., and MAZOUJIAN, G. (1986). Biochemistry and immunohistochemistry of fluid proteins of the breast in gross cystic disease. In Diseases of the Breast. C.D. Haagensen, ed. (W.B. Saunders company, New York, NY) pp. 474-500.
17. HAYES, D.F., ISAACS, C., and STEARNS, V. (2001). Prognostic factors in breast cancer: Current and new predictors of metastasis. J. Mammary Gland Biol. Neoplasia 6, 375-392.
18. HILF, R., FELDSTEIN, M.L., GIBSON, S.L., and SAVLOV, E.D. (1980). The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45, 1993-2000.
19. HOUGHTON, R.L., DILLON, D.C., MOLESH, D.A., ZEHENTNER, B.K., XU, J., JIANG, J., SCHMIDT, C., FRUDAKIS, A., REPASKY, E., MALTEZ FILHO, A., et al. (2001). Transcriptional complementarity in breast cancer: Application to detection of circulating tumor cells. Mol. Diagn. 6, 79-91.
20. HUDSON, L.G., ERTL, A.P., and GILL, G.N. (1990). Structure and inducible regulation of the human c-erb B2/neu promoter. J. Biol. Chem. 265, 4389-4393.
21. HURST, H.C. (2001). Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res. 3, 395-398.
22. HYNES, N.E., and STERN, D.F. (1994). The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198, 165-184.
23. KLIJN, J.G., BERNS, P.M., SCHMITZ, P.I., and FOEKENS, J.A. (1992). The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr. Rev. 13, 3-17.
24. KOGA, T., HORIO, Y., MITSUDOMI, T., TAKAHASHI, T., and YATABE, Y. (2004). Identification of MGB1 as a marker in the differential diagnosis of lung tumors in patients with a history of breast cancer by analysis of publicly available SAGE data. J. Mol. Diagn. 6, 90-95.
25. LEE, C.H., HSIAO, M., TSENG, Y.L., and CHANG, F.H. (2003). Enhanced gene delivery to HER-2-overexpressing breast cancer cells by modified immunolipoplexes conjugated with the anti-HER-2 antibody. J. Biomed. Sci. 10, 337-344.
26. LEYGUE, E., SNELL, L., DOTZLAW, H., HOLE, K., TROUP, S., KILLER-HITCHCOCK, T., MURPHY, L.C., and WATSON, P.H. (1999). Mammaglobin, a potential marker of breast cancer nodal metastasis. J. Pathol. 189, 28-33.
27. LI, X., GU, W., MOHAN, S., and BAYLINK, D.J. (2002). DNA microarrays: Their use and misuse. Microcirculation 9, 13-22.
28. MANNELLO, F., and GAZZANELLI, G. (2001). Prostate-specific antigen (PSA/hK3): A further player in the field of breast cancer diagnostics? Breast Cancer Res. 3, 238-243.
29. MARTH, J.D., and VARKI, A. (1999). O-Glycans. In Essentials of Glycobiology. A. Varki, ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) pp. 101-106, 537-549.
30. MASON, B.H., HOLDAWAY, I.M., MULLINS, P.R., YEE, L.H., and KAY, R.G. (1983). Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res. 43, 2985-2990.
31. MEENAKSHI, A., KUMAR, R.S., and KUMAR, N.S. (2002). ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients. J. Immunoassay Immunochem. 23, 293-305.
32. MIKSICEK, R.J., MYAL, Y., WATSON, P.H., WALKER, C., MURPHY, L.C., and LEYGUE, E. (2002). Identification of a novel breast-and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. Cancer Res. 62, 2736-2740.
33. MURPHY, L.C., LEE-WING, M., GOLDENBERG, G.J., and SHIU, R.P. (1987). Expression of the gene encoding a prolactin-inducible protein by human breast cancers in vivo: Correlation with steroid receptor status. Cancer Res. 47, 4160-4164.
34. MYAL, Y., ROBINSON, D.B., IWASIOW, B,, TSUYUKI, D., WONG, P., and SHIU, R.P. (1991). The prolactin-inducible protein (PIP/GCDFP-15) gene: Cloning, structure and regulation. Mol. Cell. Endocrinol. 80, 165-175.
35. NACHT, M., FERGUSON, A.T., ZHANG, W., PETROZIELLO, J.M., COOK, B.P., GAO, Y.H., MAGUIRE, S., RILEY, D., COPPOLA, G., LANDES, G.M., et al. (1999). Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res. 59, 5464-5470.
36. NICHOLSON, S., WRIGHT, C., SAINSBURY, J.R., HALCROW, P., KELLY, P., ANGUS, B., FARNDON, J.R., and HARRIS, A.L. (1990). Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J. Steroid Biochem. Mol. Biol. 37, 811-814.
37. PAIK, S., and PARK, C. (2001). HER-2 and choice of adjuvant chemotherapy in breast cancer. Semin. Oncol. 28, 332-335.
38. PANDHA, H.S., MARTIN, L.A., RIGG, A., HURST, H.C., STAMP, G.W., SIKORA, K., and LEMOINE, N.R. (1999). Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol. 17, 2180-2189.
39. PEGRAM, M.D., PAULETTI, G., and SLAMON, D.J. (1998). HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65-77.
40. PUNJ, V., GRAVES, J.M., and MEHTA, R.R. (2004). Effect of vitamin D analog (1alpha hydroxy D5) immunoconjugated to Her-2 antibody on breast cancer. Int. J. Cancer. 108, 922-999.
41. QUAN, C., and LU, S.J. (2003). Identification of genes preferentially expressed in mammary epithelial cells of Copenhagen rat using subtractive hybridization and microarrays. Carcinogenesis 24, 1593-1599.
42. ROSS, J.S., FLETCHER, J.A., LINETTE, G.P., STEC, J., CLARK, E., AYERS, M., SYMMANS, W.F., PUSZTAI, L., and BLOOM, K.J. (2003). The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 8, 307-325.
43. SHEK, L.L., and GODOLPHIN, W. (1988). Model for breast cancer survival: Relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res. 48, 5565-5569.
44. SHIU, R.P., and IWASIOW, B.M. (1985). Prolactin-inducible proteins in human breast cancer cells. J. Biol. Chem. 260, 11307-11313.
45. SPIZZO, G., GASTL, G., WOLF, D., GUNSILIUS, E., STEURER, M., FONG, D., AMBERGER, A., MARGREITER, R., and OBRIST, P. (2003). Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br. J. Cancer 88, 574-578.
46. STEARNS, V., YAMAUCHI, H., and HAYES, D.F. (1998). Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res. Treat. 52, 239-259.
47. SUCHY, B., AUSTRUP, F., DRIESEL, G., EDER, C., KUSIAK, I., UCIECHOWSKI, P., GRILL, H.J., and GIESING, M. (2000). Detection of mammaglobin expressing cells in blood of breast cancer patients. Cancer Lett. 158, 171-178.
48. TAYLOR-PAPADIMITRIOU, J., BURCHELL, J., MILES, D.W., and DALZIEL, M. (1999). MUC1 and cancer. Biochim. Biophys. Acta 1455, 301-313.
49. VELCULESCU, V.E., ZHANG, L., VOGELSTEIN, B., and KINZLER, K.W. (1995). Serial analysis of gene expression. Science 270, 484-487.
50. VON MENSDORFF-POUILLY, S., SNIJDEWINT, F.G., VERSTRAETEN, A.A., VERHEIJEN, R.H., and KENEMANS, P. (2000). Human MUC1 mucin: A multifaceted glycoprotein. Int. J. Biol. Markers 15, 343-356.
51. WATSON, M.A., and FLEMING, T.P. (1996). Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res. 56, 860-865.
52. WEIGELT, B., VERDUIJN, P., BOSMA, A.J., RUTGERS, E.J., PETERSE, H.L., and VAN'T VEER, L.J. (2004). Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Br. J. Cancer 90, 1531-1537.
53. WILCOX, D.A., OLSEN, J.C., ISHIZAWA, L., GRIFFITH, M., and WHITE, G.C., 2nd. (1999). Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Proc. Natl. Acad. Sci. USA 96, 9654-9659.
54. YOSHIDA, M., ABE, O., UCHINO, J., KIKUCHI, K., ABE, R., ENOMOTO, K., TOMINAGA, T., FUKAMI, A., SAKAI, K., KOYAMA, H., et al. (1997). Efficacy of post-operative adjuvant therapy for stage IIIa breast cancer: Futraful vs futraful+tamoxifen for ER-positive patients and futraful vs futraful+adriamycin for ER-negative breast cancer. Breast Cancer 4, 103-113.
55. ZACH, O., KASPARU, H., KRIEGER, O., HEHENWARTER, W., GIRSCHIKOFSKY, M., and LUTZ, D. (1999). Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J. Clin. Oncol. 17, 2015-2019.
56. ZHAO, X.Y., and HUNG, M.C. (1992). Negative autoregulation of the neu gene is mediated by a novel enhancer. Mol. Cell. Biol. 12, 2739-2748.
57. ZHU, K., BERNARD, L.J., LEVINE, R.S., and WILLIAMS, SM. (1997). Estrogen receptor status of breast cancer: A marker of different stages of tumor or different entities of the disease? Med. Hypotheses 49, 69-75.
58. ZIMMERMAN, R.L., FOGT, F., and GOONEWARDENE, S. (2000). Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions. Cancer 90, 230-234.